Details for Patent: 11,241,377
Which drugs does patent 11,241,377 protect, and when does it expire?
Patent 11,241,377 protects RISVAN and is included in one NDA.
This patent has one hundred and ninety-six patent family members in thirty-six countries.
Summary for Patent: 11,241,377
| Title: | Antipsychotic injectable depot composition |
| Abstract: | The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks. |
| Inventor(s): | Ibon GUTIERRO ADURIZ, Maria Teresa Gomez Ochoa |
| Assignee: | Laboratorios Farmaceuticos Rovi SA |
| Application Number: | US16/656,167 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Device; |
Drugs Protected by US Patent 11,241,377
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Labs Farms Rovi Sa | RISVAN | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 214835-001 | Mar 29, 2024 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | INTRAMUSCULAR ADMINISTRATION OF RISPERIDONE IN EXTENDED RELEASE INJECTABLE SUSPENSION FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Start Trial | ||||
| Labs Farms Rovi Sa | RISVAN | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 214835-002 | Mar 29, 2024 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | INTRAMUSCULAR ADMINISTRATION OF RISPERIDONE IN EXTENDED RELEASE INJECTABLE SUSPENSION FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,241,377
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 3524 | ⤷ Start Trial | |||
| Australia | 2011260318 | ⤷ Start Trial | |||
| Australia | 2013269546 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
